Beaufort Securities reaffirmed their speculative buy rating on shares of Tissue Regenix Group PLC (LON:TRX) in a research note issued to investors on Thursday morning.

Separately, Jefferies Group raised their price target on shares of Tissue Regenix Group PLC from GBX 35 ($0.43) to GBX 40 ($0.50) and gave the company a buy rating in a research report on Monday, July 11th.

Shares of Tissue Regenix Group PLC (LON:TRX) traded down 4.2092% on Thursday, hitting GBX 17.1226. 1,107,597 shares of the company’s stock were exchanged. Tissue Regenix Group PLC has a 12 month low of GBX 12.70 and a 12 month high of GBX 22.50. The firm’s market cap is GBX 127.25 million. The stock’s 50 day moving average is GBX 19.16 and its 200 day moving average is GBX 19.36.

Tissue Regenix Group PLC Company Profile

Tissue Regenix Group plc is a medical technology company. The Company is engaged in the development of regenerative products to make replacement native tissue using biological (human and animal) tissues. It operates through Cardiac, Wound Care and Orthopaedics divisions. Its decellularisation (dCELL) technology removes deoxyribonucleic acid and other cellular material from tissue leaving an acellular scaffold, which is not rejected by the patient’s body.

Receive News & Ratings for Tissue Regenix Group PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tissue Regenix Group PLC and related companies with's FREE daily email newsletter.